Skip to search formSkip to main contentSkip to account menu

ustekinumab

Known as: Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer, Ustekinumab [Chemical/Ingredient] 
An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with… 
National Institutes of Health

Related topics

Related topics

9 relations
0.5 ML ustekinumab 90 MG/ML Prefilled Syringe26 ML ustekinumab 5 MG/ML Injection [Stelara]In Bloodantigen binding

Narrower (2)

CNTO 1275Stelara

Broader (1)

Dermatologic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature
BackgroundUstekinumab is a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 which is… 
Review
2014
Review
2014
From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other…
Review
2014
Review
2014
Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease.
  • A. Kaser
  • Best practice & research. Clinical…
  • 2014
  • Corpus ID: 3277888
2013
2013
Weight gain and tumour necrosis factor‐alpha inhibitors in patients with psoriasis
To compare the effect of anti‐tumour necrosis factor (TNF)‐α therapies with agents that do not target TNF‐α on bodyweight and… 
Review
2013
Review
2013
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential
Ustekinumab (UST) is a fully human immunoglobulin G1κ (IgG1κ) monoclonal antibody against common sub-unit p40 of interleukin-12… 
Review
2013
Review
2013
Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.
Review
2012
Review
2012
Efficacy of systemic therapies for moderate‐to‐severe psoriasis: a systematic review and meta‐analysis of long‐term treatment
Background  Despite the chronicity of psoriasis, most systematic reviews focus on short‐term treatment. 
Review
2012
Review
2012
Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review
Background: Therapy with tumour necrosis factor α (TNF) inhibitors can be associated with paradoxical reactions, namely the de… 
2010
2010
Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy.
BACKGROUND Ustekinumab is a new immunosuppressive anti-psoriasis agent. The drug targets the p40 subunit of IL-12 and IL-23 and… 
Highly Cited
2009
Highly Cited
2009
Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease
OBJECTIVES:Ustekinumab induction therapy was studied in a placebo-controlled trial of patients with Crohn's disease (CD; n=104… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)